Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages between 18-40 years~* Males \& females~* patients between the ages of 18 and 53 who met the diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (20), with a minimum disease duration of two years.~* stable on risperidone for a minimum of 8 weeks~* clinically stable for at least 4 weeks prior to study.~* willing to give informed consent.~* able to take medication orally.~Exclusion Criteria:~* Acute, unstable, significant or untreated medical illness beside schizophrenia;~* Pregnant or breast-feeding females;~* History of substance abuse or dependence in the past 3 months.~* Known contraindication to pentoxifylline treatment.~* Any serious or life-threatening medical conditions or neurological problem, severe extrapyramidal symptoms, history of abnormal bleeding, presence of hypothyroidism, renal disease, cardiovascular problems, rising liver transaminases to 3 times the upper limit of normal or higher

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Equivalent Placebo will be given
- Pentoxifylline group (Type: EXPERIMENTAL): Pentoxifylline will be given orally at 800 mg a day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).